Phase 2 study of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy in patients with refractory pancreatic cancer (TRIPLE-R).
Sign Up to like & getrecommendations! Published in 2022 at "European journal of cancer"
DOI: 10.2139/ssrn.4165619
Abstract: BACKGROUND Interleukin-6 blockade and radiation combined with immunotherapy may modulate the tumour microenvironment to overcome immune resistance. We assessed the efficacy of ipilimumab, nivolumab, and tocilizumab combined with stereotactic body radiotherapy (SBRT) in patients with… read more here.
Keywords: ipilimumab nivolumab; combined stereotactic; tocilizumab combined; nivolumab tocilizumab ... See more keywords